Non-Steroidal Anti-Inflammatory Drug (NSAID) Response and Central Sensitization of Pain in Women With Dysmenorrhea

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2025

Conditions
DysmenorrheaMenstrual PainNon-steroidal Anti-inflammatory Drug
Interventions
DRUG

Sodium Naproxen

One dose of 550mg sodium naproxen taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).

DRUG

Placebo

One dose of placebo capsule taken at the onset of at least moderate pain after menstrual bleeding has started (i.e., at least 6/10 on the 0-10 numeric rating scale).

Trial Locations (1)

02478

McLean Hospital, Belmont

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Endeavor Health

OTHER

lead

Mclean Hospital

OTHER